Details of the Drug

General Information of Drug (ID: DMS4XFI)

Drug Name
OPT-302
Indication
Disease Entry ICD 11 Status REF
Diabetic macular edema 9B71.02 Phase 2 [1]
Cross-matching ID
TTD ID
DNA7I1

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Vascular endothelial growth factor C (VEGFC) TT0QUFV VEGFC_HUMAN Inhibitor [2]
Vascular endothelial growth factor D (VEGFD) TTOM5H4 VEGFD_HUMAN Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03345082) A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Opthea.